INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

People assigned to a diet, food or program and measured.

287 studies · page 4 of 12

2015 / Multicenter randomized, placebo-controlled, double-blind trial

Adding curcumin to mesalamine therapy induced higher rates of clinical and endoscopic remission in patients with mild-to-moderate active ulcerative colitis.

Fifty patients with active mild-to-moderate ulcerative colitis unresponsive to maximum mesalamine therapy were randomized to receive curcumin capsules (3 g/day, n = 26) or identical placebo (n = 24) for 1 month alongside mesalamine. In the intention-to-treat analysis, 53.8% (14/26) of patients in the curcumin group achieved clinical remission at week 4 compared with 0% (0/24) in the placebo group (P = .01; OR, 42; 95% CI, 2.3-760). Clinical response occurred in 65.3% of the curcumin group vs. 12.5% in the placebo group (P < .001). Endoscopic remission was observed in 38% (8/22) evaluated in the curcumin group vs. 0% (0/16) in the placebo group (P = .043). Adverse events were rare and comparable between groups.

Lang A, Salomon N, Wu JC, et al. Clin Gastroenterol Hepatol, 2015. PMID 25724700

2015 / Multicenter, double-blind, randomized crossover trial

In children aged 4–6 years, single doses of erythritol up to 15 g were well tolerated, with diarrhea or severe symptoms observed at 20 g and 25 g.

A multicenter trial examined the gastrointestinal tolerance of a single oral dose of erythritol (5, 15, 20, or 25 g) versus an isosweet sucrose placebo in a 250-ml beverage consumed between meals by children aged 4-6 years. Statistically significantly more episodes of diarrhea and/or severe GI symptoms occurred in the 20 and 25 g groups compared with placebo, but not in the 5 and 15 g groups. Stool consistency on the Bristol stool scale was lower in the 15, 20, and 25 g groups during the first 24 hours, while nausea, vomiting, borborygmi, excess flatus, and abdominal pain did not differ significantly from placebo at any dose. The researchers concluded that up to 15 g (0.73 g/kg body weight) was well tolerated, serving as the no observed effect level for diarrhea or severe GI symptoms.

Jacqz-Aigrain E, Kassai B, Cornu C, et al. Eur J Clin Nutr, 2015. PMID 25744158

2015 / Clinical study with intervention and case-control components

A bowel stimulation regimen of high fiber, fluid, exercise, and a prokinetic reduced colon transit time, fecal load, and abdominal symptoms.

Studies examined whether fecal retention contributes to functional bowel disorders, appendicitis, and hemorrhoids. Patients with functional bowel disorders had significantly increased colon transit time (CTT) and fecal load compared to controls. An intervention combining a fiber-rich diet, fluid, physical activity, and a prokinetic drug significantly reduced CTT, fecal load, bloating, and abdominal pain, while improving defecation patterns. Surgical interventions (colectomy, stapled hemorrhoidopexy) were evaluated in refractory constipation and hemorrhoid cohorts.

Raahave D Dan Med J, 2015. PMID 25748875

2015 / Randomized controlled trial

Daily shiitake mushroom consumption improved markers of immune function in healthy young adults.

Fifty-two healthy adults consumed 5 g or 10 g of dried shiitake mushrooms daily for 4 weeks in a parallel-group trial. Mushroom intake increased ex vivo proliferation of γδ-T cells by 60% and natural killer T cells twofold (both p < 0.0001), along with greater activation receptor expression. Salivary secretory immunoglobulin A increased and serum C-reactive protein decreased, accompanied by distinct shifts in cytokine secretion profiles.

Dai X, Stanilka JM, Rowe CA, et al. J Am Coll Nutr, 2015. PMID 25866155

2015 / Two-week dietary exchange trial

A 2-week diet swap between African Americans and rural Africans led to reciprocal changes in mucosal cancer biomarkers, microbiota, and metabolome markers.

Researchers performed supervised 2-week food exchanges where African Americans consumed a high-fibre, low-fat African-style diet and rural Africans consumed a high-fat, low-fibre western-style diet. Compared with usual diets, the dietary switch led to reciprocal changes in mucosal biomarkers of cancer risk, microbiota, and the metabolome. In African Americans, these changes were highlighted by increased saccharolytic fermentation and butyrogenesis alongside suppressed secondary bile acid synthesis.

O'Keefe SJ, Li JV, Lahti L, et al. Nat Commun, 2015. PMID 25919227

2015 / Intervention trial with periodic fecal sampling

A gut microbiota-targeted dietary intervention altered fecal menaquinones, which were linked to specific bacterial taxa but not cardiometabolic markers.

Researchers evaluated fecal menaquinone profiles, gut microbiota structure, and cardiometabolic biomarkers in 77 overweight Chinese adults consuming a prescribed diet designed to alter gut microbiota composition. Covariance among fecal menaquinones identified two distinct groups ('menaquinotypes'), characterized by differences in MK5, MK9-MK13, and relative abundance of species mostly within Prevotella and Bacteroides. During the intervention, fecal MK4, MK6, and MK8 decreased (P < 0.05), and longitudinal shifts in >100 operational taxonomic units related to altered individual menaquinones. However, neither individual menaquinones nor menaquinotypes were longitudinally associated with markers of glycemia, insulin resistance, or inflammation.

Karl JP, Fu X, Wang X, et al. Am J Clin Nutr, 2015. PMID 26016865

2015 / Randomized crossover trial

Butyrylated high-amylose maize starch prevented red meat-induced increases in rectal O6MeG adducts in healthy humans.

In a randomized crossover trial, 23 healthy individuals consumed 300 g/d of cooked red meat alone (HRM) or with 40 g/d of butyrylated high-amylose maize starch (HRM+HAMSB) for 4 weeks each, separated by a 4-week washout. The HRM diet increased rectal O6MeG adducts by 21% relative to baseline (P < 0.01), but the addition of HAMSB prevented this increase. Epithelial proliferation increased with both diets compared to baseline, but was lower following HRM+HAMSB compared to HRM (P < 0.05). HRM+HAMSB also increased stool SCFA excretion by over 20% (P < 0.05) and altered fecal microbiota abundances.

Le Leu RK, Winter JM, Christophersen CT, et al. Br J Nutr, 2015. PMID 26084032

2015 / Double-blind randomised placebo-controlled study

In Crohn's disease patients in remission, 2000 IU/day vitamin D for 3 months maintained intestinal permeability and increased cathelicidin levels.

Twenty-seven Crohn's disease patients in remission were assigned to 2000 IU/day vitamin D or placebo for 3 months. At 3 months, 25(OH)D levels were significantly higher in the treated group (p < 0.001), with increased LL-37 concentrations (p = 0.050) and maintenance of intestinal permeability, whereas placebo patients experienced increases in small bowel (p = 0.018) and gastro-duodenal permeability (p = 0.030). Patients reaching 25(OH)D ≥ 75 nmol/L at 3 months had significantly lower CRP (p = 0.019), higher Quality of Life (p = 0.037), and higher LL-37 concentrations (p < 0.001) compared to those with levels < 75 nmol/L.

Raftery T, Martineau AR, Greiller CL, et al. United European Gastroenterol J, 2015. PMID 26137304

2015 / Randomized controlled trial

Lactobacillus casei Shirota did not significantly alter TMAO in metabolic syndrome patients.

In an open-label randomized trial, 30 participants with metabolic syndrome were assigned to consume Lactobacillus casei Shirota three times daily (6.5 × 10^9 CFU) or standard care for 12 weeks; 28 completed the protocol. Plasma TMAO concentrations declined in both the probiotic group (4.66 ± 2.66 to 4.31 ± 2.04 μM) and controls (4.64 ± 2.75 to 4.40 ± 2.14 μM). The net changes (-0.25 ± 2.39 vs. -0.34 ± 2.23 μM) did not differ significantly between arms (p = 0.510).

Tripolt NJ, Leber B, Triebl A, et al. Atherosclerosis, 2015. PMID 26188537

2015 / Randomized controlled trial

A low-FODMAP diet reduced irritable bowel syndrome symptoms similarly to traditional dietary advice.

Seventy-five patients meeting Rome III criteria for irritable bowel syndrome were randomized to a low-FODMAP diet (n = 38) or traditional dietary advice (n = 37) for four weeks. Symptom severity decreased significantly in both groups (p < 0.0001), with no significant difference between treatments (p = 0.62). Reductions in severity scores of 50 or more occurred in 50% of the low-FODMAP group and 46% of the traditional diet group.

Böhn L, Störsrud S, Liljebo T, et al. Gastroenterology, 2015. PMID 26255043

2015 / Randomized crossover trial

A 3-day barley kernel bread intervention improved insulin sensitivity and increased gut hormones in healthy middle-aged adults.

Twenty middle-aged participants consumed either a barley kernel-based bread (BB) or a reference white wheat bread for 3 consecutive days in a randomized crossover design, followed by a standardized breakfast on day 4. Compared to reference bread, 3 days of BB increased fasting plasma GLP-1 by 56%, postprandial plasma GLP-2 by 13%, and postprandial plasma PYY by 18%. BB intervention also increased breath H2 excretion by 363% and fasting serum SCFAs by 18%, while decreasing blood glucose responses by 22% and serum insulin responses by 17%. Insulin sensitivity index (ISIcomposite) was improved by 25% following the BB intervention.

Nilsson AC, Johansson-Boll EV, Björck IM Br J Nutr, 2015. PMID 26259632

2015 / Intervention trial (pre-post dietary challenge)

A short-term high-fat diet increased postprandial, but not fasting, plasma TMAO concentrations in young, nonobese men.

Following a 2-week eucaloric control diet, 10 nonobese men consumed a eucaloric high-fat diet (55% fat) for 5 days. Fasting plasma TMAO did not increase significantly after the diet (1.83 ± 0.21 vs 1.6 ± 0.24 μmol/L). However, postprandial plasma TMAO was significantly higher across 4 hours following a high-fat meal challenge compared with baseline: hour 1 (2.15 ± 0.28 vs 1.7 ± 0.30 μmol/L), hour 2 (2.3 ± 0.29 vs 1.8 ± 0.32 μmol/L), hour 3 (2.4 ± 0.34 vs 1.58 ± 0.19 μmol/L), and hour 4 (2.51 ± 0.33 vs 1.5 ± 0.12 μmol/L; all P < .05).

Boutagy NE, Neilson AP, Osterberg KL, et al. Nutr Res, 2015. PMID 26265295

2015 / Double-blind randomized crossover study

In healthy volunteers, 18 mg of quinine significantly reduced subsequent calorie intake and increased postprandial CCK release.

Twenty healthy volunteers randomly received an acid-resistant capsule containing either placebo or 18 mg of hydrochloride (HCl) quinine on 2 separate days, followed by an ad libitum meal 60 minutes later. Calorie intake was significantly lower with quinine compared to placebo (514 ± 248 vs 596 ± 286 kcal; P = 0.007). Higher CCK ΔT90 vs T0 and ΔT90 vs T60 were observed with quinine versus placebo (0.70 ± 0.69 vs 0.10 ± 0.86 ng/mL, P = 0.026; 0.92 ± 0.75 vs 0.50 ± 0.55 ng/mL, P = 0.033). The calorie reduction was significant in PTC tasters (526 ± 275 vs 659 ± 320 kcal; P = 0.005) but not in PTC non-tasters (499 ± 227 vs 519 ± 231 kcal; P = 0.525).

Andreozzi P, Sarnelli G, Pesce M, et al. J Neurogastroenterol Motil, 2015. PMID 26351252

2015 / Randomized crossover trial

Palm date consumption reduced fecal water genotoxicity and improved bowel movements in adults.

A crossover trial randomized 22 healthy adults to consume approximately 50 g of palm dates or a control carbohydrate supplement daily for 21 days separated by a 14-day washout. Date intake did not alter short-chain fatty acids or selected bacterial groups. However, date intake significantly increased bowel movement frequency (P<0.01; n=21), reduced stool ammonia (P<0.05; n=21), and lowered fecal water genotoxicity compared to control (P<0.01; n=21).

Eid N, Osmanova H, Natchez C, et al. Br J Nutr, 2015. PMID 26428278

2015 / Prospective cohort and randomized controlled trial

A machine-learning algorithm predicted personalized postprandial glycemic responses to meals.

Researchers monitored continuous glucose across 46,898 meals in an 800-person cohort and observed high variability in responses to identical foods. A machine-learning model integrating clinical parameters, diet, anthropometrics, physical activity, and gut microbiota predicted personalized glycemic responses, which was validated in 100 participants. A blinded randomized dietary intervention guided by the algorithm significantly reduced postprandial glycemic responses and altered gut microbiota composition.

Zeevi D, Korem T, Zmora N, et al. Cell, 2015. PMID 26590418

2015 / Randomized controlled crossover pilot study

Whole grain bread snack increased satiety, decreased remaining energy intake, and reduced postprandial peptide YY versus conventional bread in young adults.

In a randomized controlled crossover pilot study, 11 university students consumed either a conventional or whole grain bread mid-morning snack across two testing days with standardized breakfast, test-snacks, and ad libitum lunch. Compared with conventional bread, whole grain bread increased satiety perception, decreased remaining energy intake during the testing day, and decreased postprandial peptide YY response (p < 0.005).

Santaliestra-Pasías AM, Garcia-Lacarte M, Rico MC, et al. Int J Food Sci Nutr, 2015. PMID 27199158

2014 / Intervention trial

Ingested Lactobacillus plantarum in fermented milk increased in feces during consumption but returned to baseline after discontinuation.

Sixty-one subjects consumed daily doses of fermented milk containing 2 × 10^11 cells of L. plantarum Lp115 for different periods of time, and the microorganism was monitored in fecal microbiota via qPCR. L. plantarum was detected and quantified in all subjects during ingestion, with statistically significant increases compared to time zero (P = 0.001). However, at 15 and 45 days after discontinuing supplementation, counts returned to baseline levels. Longer consumption periods did not lead to increased bacterial levels in stool during postconsumption evaluations (P = 0.001).

Costa GN, Marcelino-Guimarães FC, Vilas-Bôas GT, et al. Appl Environ Microbiol, 2014. PMID 24271176

2014 / Clinical dietary intervention study

Short-term plant- or animal-based diets rapidly alter human gut microbial communities.

Consuming diets consisting strictly of animal or plant products rapidly shifted gut microbial community composition and surpassed differences between individuals. The animal diet elevated bile-tolerant microbes such as Alistipes, Bilophila, and Bacteroides, while lowering plant polysaccharide-fermenting Firmicutes. In addition, foodborne organisms transiently colonized the gastrointestinal tract during both dietary phases.

David LA, Maurice CF, Carmody RN, et al. Nature, 2014. PMID 24336217

2014 / Randomized controlled trial

Dark roast coffee stimulated gastric acid secretion less effectively than market blend coffee

In nine healthy volunteers, intragastric pH was assessed following administration of bicarbonate with or without 200 mL of dark roast or market blend coffee. Dark roast coffee had higher N-methylpyridinium concentrations but lower chlorogenic acids, trigonelline, and C5HT compared to market coffee. Gastric acid secretion was less effectively stimulated by the dark roast beverage than by the market blend.

Rubach M, Lang R, Bytof G, et al. Mol Nutr Food Res, 2014. PMID 24510512

2014 / Randomized crossover trial

Ancient wheat products reduced irritable bowel syndrome symptoms compared with modern wheat.

A randomized crossover trial in 20 adults with moderate irritable bowel syndrome compared 6-week replacement diets of ancient versus modern wheat products. Ancient wheat significantly decreased abdominal pain (P < 0.0001), bloating (P = 0.004), tiredness (P < 0.0001), and circulating levels of proinflammatory cytokines, including IL-6 and IL-17. Modern wheat products caused no significant improvements.

Sofi F, Whittaker A, Gori AM, et al. Br J Nutr, 2014. PMID 24521561

2014 / Double-blind randomized controlled pilot trial

In a pilot trial of IBS patients, ginger was well tolerated but did not perform better than placebo in reducing symptoms.

Forty-five IBS patients were randomized to receive placebo, 1 g of ginger, or 2 g of ginger daily for 28 days. Responders (defined as having at least a 25% reduction in IBS-SS) made up 57.1% of the placebo group, 46.7% of the 1 g ginger group, and 33.3% of the 2 g ginger group. Adequate relief was reported by 53.3% on placebo and 53.3% in both ginger groups combined. Side effects were mild, occurring in 35.7% of the placebo group and 16.7% of the ginger groups.

van Tilburg MA, Palsson OS, Ringel Y, et al. Complement Ther Med, 2014. PMID 24559811

2014 / Randomized crossover trial

Gluten challenge induced short-term feelings of depression in non-celiac gluten sensitivity.

A randomized double-blind crossover trial tested three-day challenges of gluten (16 grams per day), whey, or placebo in 22 adults with irritable bowel syndrome controlled on a gluten-free diet. Gluten ingestion caused higher state depression scores compared with placebo (mean difference 2.03, 95% CI 0.55 to 3.51, P = 0.010), but not compared with whey. Cortisol levels and gastrointestinal symptoms did not differ across the three challenges.

Peters SL, Biesiekierski JR, Yelland GW, et al. Aliment Pharmacol Ther, 2014. PMID 24689456

2014 / Double-blind randomized controlled trial

Ginger supplementation reduced antiretroviral-induced nausea and vomiting in HIV-positive patients.

In a double-blind trial, 102 HIV-positive patients were randomized to receive either 500 mg ginger or placebo twice daily 30 minutes before each antiretroviral dose for 14 days. During the first 2 weeks, nausea was experienced by 56.4% (29 patients) in the ginger group versus 90.2% (46 patients) in the placebo group (p = 0.001). Additionally, 9.8% (5 patients) in the ginger group versus 47.1% (24 patients) in the placebo group reported at least one episode of vomiting (p = 0.01).

Dabaghzadeh F, Khalili H, Dashti-Khavidaki S, et al. Expert Opin Drug Saf, 2014. PMID 24820858

2014 / Randomized controlled three-arm crossover trial and in vitro study

Evening meals with wholegrain rye kernel bread or boiled rye kernels reduced subsequent ad libitum lunch energy intake and increased breath hydrogen excretion.

Twelve healthy men consumed three isocaloric evening test meals: white wheat bread (WWB), wholegrain rye kernel bread (RKB), or boiled rye kernels (RK). While test meals did not differ in subjective appetite sensations the following morning, ad libitum lunch energy intake was reduced by 11% after RKB (P < 0.01) and 7% after RK (P < 0.05) compared with WWB. Breath hydrogen excretion was significantly increased following RKB and RK meals compared with WWB (P < 0.01 and P < 0.05, respectively). In vitro fermentation showed increased relative quantities of Bifidobacterium and decreased Bacteroides for both rye foods compared with inoculum (P < 0.001).

Ibrügger S, Vigsnæs LK, Blennow A, et al. Appetite, 2014. PMID 24874564